Important Securities Class Action Deadline for Mereo BioPharma Investors Approaching Soon

Reminder for Mereo BioPharma Investors: Class Action Deadline Approaching

In a significant development for investors of Mereo BioPharma Group plc, the law firm Faruqi & Faruqi, LLP has issued a reminder regarding the upcoming deadline for a securities class action. This lawsuit is focused on claims related to potential misconduct by the company during a critical period.

The Federal class action law suit filed against Mereo is primarily concerned with allegations that the company, along with its executives, made misleading statements that led to substantial investor losses. Investors who purchased or acquired shares between June 5, 2023, and December 26, 2025 are particularly encouraged to take note of this announcement, as the lead plaintiff deadline is set for April 6, 2026. They are urged to reach out and discuss their legal rights and options if they have suffered losses due to these alleged misrepresentations.

An interesting aspect of this case revolves around the outcomes of two pivotal Phase 3 clinical trials, namely ORBIT and COSMIC, involving the drug setrusumab. As previously reported, the results from these trials fell short of expectations, failing to meet their primary endpoints aimed at reducing clinical fracture rates compared to the placebo group and bisphosphonates.

On December 29, 2025, Mereo announced the disappointing results during an early market release, stating that both trials had not succeeded in achieving their primary objectives. However, the trials did show improvements in bone mineral density on secondary endpoints, but the market's reaction was overwhelmingly negative. As a direct consequence of this news, Mereo's stock price plummeted by $2.02 per share, marking an 87.64% decline, ultimately closing at a mere $0.28 per share.

Faruqi & Faruqi, LLP, based in New York with additional offices across the U.S., has a notable history, having recovered hundreds of millions for investors since its inception in 1995. The firm not only encourages those affected by the decline in Mereo's stock to get in touch but also invites anyone with relevant information regarding the company's conduct to reach out.

The role of the lead plaintiff is crucial in class action lawsuits, as this person will oversee the litigation on behalf of the entire class. Any member of the proposed class can apply to serve in this capacity or simply choose to remain an absent class member. It’s essential to understand that opting to serve as a lead plaintiff does not affect one's ability to recover in the settlement.

For investors contemplating their next steps, Faruqi & Faruqi provides contact information to get directly in touch with Senior Partner James (Josh) Wilson, who specializes in securities litigation. He is available via direct lines 877-247-4292 or 212-983-9330 (Ext. 1310).

Investors are encouraged to stay informed and proactive regarding their rights, particularly as the deadline approaches. For more detailed information about the securities class action and to examine the allegations in depth, visit the firm’s dedicated page for Mereo BioPharma at www.faruqilaw.com/MREO. Additionally, updates can be followed on social media platforms like LinkedIn, X, and Facebook.

In this fast-paced financial landscape, staying informed is essential. Those affected by the performance of Mereo BioPharma are urged to take action before the deadline closes in.